Acoramidis

Acoramidis is the medicine in Attruby, a tablet sold as acoramidis hydrochloride. The US label calls it a transthyretin stabilizer and says it is a selective stabilizer of transthyretin (TTR), the protein involved in transthyretin amyloidosis. The label gives its indication as the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis in adults, to reduce cardiovascular death and cardiovascular-related hospitalization. The atlas holds no trial results for it.

Also called Attruby · Acoramidis hydrochloride

  • Drug
  • In this atlas

Overview

Technical summary

RxNorm ingredient 2698312 (acoramidis); the label names the salt acoramidis hydrochloride (RxNorm 2698313), whose UNII VY9C88C2NV is a broad match to the ingredient. RxClass lists the FDA established pharmacologic class Transthyretin Stabilizer, so the record is filed under the class page. MeSH has no descriptor for acoramidis (an exact-label lookup returned an empty list on 2026-11-19). The label read is the BridgeBio Pharma, Inc. label for Attruby, application NDA216540, effective 2026-06-29 in openFDA; it is the only openFDA label returned for the ingredient, and Drugs@FDA lists one application with one product. The record read has no boxed warning section. This page records the label indication, the class and the mechanism sentences only: no trial result and no dose is given.

About this drug

Level
Substance
Mechanism
The label says acoramidis is a selective stabilizer of transthyretin (TTR): it binds TTR at thyroxine binding sites and slows dissociation of the TTR tetramer into its constituent monomers.

Classification codes

  • UNII VY9C88C2NV Acoramidis hydrochloride

Claims and evidence

Context Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, as described in the US label of Attruby

Recipient
Recipient not specified
Population
Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM), as the indications section of the label describes them. The passages read give no other age range.
Care setting
Prescription medicine, as described in the US label
Geography
United States (label of the US Food and Drug Administration)
Life stage
Not stated in the label passages read
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (label statement)
Eligibility: 1 inclusion criterion; exclusion criteria not stated
Included
  • Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM)
Excluded
None stated
  • Description Evidence stage not applicable Certainty not assessed

    The US label of Attruby (acoramidis hydrochloride tablets; BridgeBio Pharma, Inc., application NDA216540; the version dated 2026-06-29 in openFDA) calls the product a transthyretin stabilizer. It lists the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults, to reduce cardiovascular death and cardiovascular-related hospitalization, as the indication.

    Applies to Recipient not specified Adults with the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis, as described in the US label of Attruby

    Certainty method
    Not assessed
    Limitations
    This claim records what one US label says the medicine is indicated for. It is not a finding about how well the medicine works, and the atlas holds no trial result for it. The label has no boxed warning in the record read. Contraindications, other warnings, interactions, the pregnancy, lactation and pediatric sections and dosing were not recorded. Labels change, and openFDA's own disclaimer says not to rely on it for decisions about medical care.
    Last checked
    2026-11-19
    Next evidence check due
    Not scheduled
    Sources and citations (4)
    1. Background openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].openfda.application_number[0]
      How it applies
      Application number of the label read, NDA216540.
      Retrieved
      Source effective date
      2026-06-29
      Source state
      Current
      Version fingerprint
      438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    2. Background openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].effective_time
      How it applies
      Effective date of the label text read, 20260629.
      Retrieved
      Source effective date
      2026-06-29
      Source state
      Current
      Version fingerprint
      438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    3. Supports openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].indications_and_usage[0], highlights sentence
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-ACO-LB-04).
      Retrieved
      Source effective date
      2026-06-29
      Source state
      Current
      Version fingerprint
      438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.
    4. Supports openFDA drug label record for acoramidis hydrochloride tablets (Attruby), BridgeBio Pharma, Inc. label: indications, mechanism, class wording

      Regulator · U.S. Food and Drug Administration (openFDA) · Edition The openFDA drug label record for set id 913552ef-875d-4cb7-bf05-a7d20a394c38 (manufacturer BridgeBio Pharma, Inc., application NDA216540), returned on 2026-11-19. The label text is dated 2026-06-29 (effective_time). It is the only openFDA label record for this ingredient returned by an openFDA generic-name search on 2026-11-19.

      Locator
      results[0].indications_and_usage[0], highlights sentence, benefit
      How it applies
      Label passage quoted in the research quote table (Q-W4K28-ACO-LB-05).
      Retrieved
      Source effective date
      2026-06-29
      Source state
      Current
      Version fingerprint
      438841cd72e10724b29ff01d969d03880c7e1fbbe08e9dfb153a94d3e3fa2f7f
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication, as the openFDA licence page states (fetched 2026-11-19, sha256 7fda0041a24f8d7139a1781d4462ae39643a2ee6f3b0f079946c989a8e1982d2, hash only). Only short passages are quoted. The raw record is committed in the atlas repository.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Record details

Record id
cardio:acoramidis
Content hash
9eed0e120ec3b2f3557d5ed715dbb373f512c83990889481de2ce7da1ec29ac7